Clinical Trials Browser

INDUSTRY × Leukemia, Myeloid, Acute × Transplantation Conditioning × Clear all

NCT04395092 2021-06-22

Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Phase 2 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute